Compare FMC Corp (FMC) vs Teladoc Health Inc (TDOC) Price & Performance

FMC Corporation (FMC) trades at $11.61, up 8.3% today, but remains in a challenging fundamental position with a net income margin of -72.93% and negative ROE of -80.78% for 2025. The company is actively restructuring, securing a $400 million minority investment from Tessenderlo Group and planning a $114 million property sale to reduce its $3.03 billion long-term debt. Technical indicators are bearish, with the stock trading near key support at $11. Recent news highlights progress on its new herbicide, rimisoxafen, including a regulatory submission to the EPA and a partnership with Corteva.

The outlook is cautious. While aggressive debt reduction and new product pipelines offer potential, deep losses and declining revenue pose significant risks. The analyst consensus is mixed (47.6% Buy, 50% Hold) with a $16 price target, suggesting modest upside if turnaround efforts succeed, but high execution risk remains the primary concern for investors.

TDOC trades at $9.56, up 3.13% with bullish technical signals from moving averages. The company reported mixed Q1 2026 earnings, missing expectations with a -$0.36 EPS, but maintains strong revenue of $2.53B and a gross margin of 69.29%. Recent partnership expansions with Walmart highlight growth initiatives, though net losses persist at -$200.32M. Analyst consensus is mixed with 35.71% buy ratings but a price target below current levels at $8.75.

The outlook remains cautious due to ongoing net losses and negative cash flow trends, with net cash flow at -$517.24M in 2025. Key risks include competitive pressures and execution challenges, but cost-cutting and market expansion could support recovery. Investors should weigh the low P/S ratio of 0.69 against profitability concerns.